Please try another search
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Benjamin J. Zeskind | 40 | 2008 | Co-Founder, President, CEO & Director |
Peter Feinberg | 61 | 2021 | Director |
Tanios Bekaii-Saab | - | - | Member of Scientific Advisory Board |
Diana F. Hausman | 60 | 2022 | Independent Director |
Mitesh J. Borad | - | - | Member of Scientific Advisory Board |
Daniel Ahn | - | - | Member of Scientific Advisory Board |
Bijan Nejadnik | 61 | - | Member of Scientific Advisory Board |
Denis C. Guttridge | - | - | Member of Scientific Advisory Board |
Robert J. Carpenter | 78 | 2008 | Co-Founder & Chair Emeritus |
Douglas A. Lauffenburger | - | - | Co-Chairman of Scientific Advisory Board |
Laurie Bartlett Keating | 70 | 2021 | Independent Director |
Max Artyomov | - | - | Co-Chairman of Scientific Advisory Board |
Ann Elyse Berman | 72 | 2021 | Independent Chair |
Thomas J. Schall | 65 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review